Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:FHTX NASDAQ:GLUE NASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$2.83-5.7%$2.10$1.47▼$17.31$73.09MN/A261,563 shs86,600 shsFHTXFoghorn Therapeutics$4.99-5.0%$5.05$2.94▼$10.25$292.64M3.05112,799 shs171,664 shsGLUEMonte Rosa Therapeutics$4.79-3.2%$4.95$3.50▼$12.40$304.47M1.42439,912 shs578,534 shsRNACCartesian Therapeutics$12.33-3.7%$11.27$8.46▼$26.50$332.47M0.4371,639 shs77,855 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics-5.67%-21.39%+77.99%+15.98%-76.02%FHTXFoghorn Therapeutics-4.95%-19.39%+0.81%+17.69%-28.92%GLUEMonte Rosa Therapeutics-3.23%-15.52%+1.27%-3.62%+5.97%RNACCartesian Therapeutics-3.75%-7.50%+8.44%-2.91%-24.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTVArtiva Biotherapeutics2.1211 of 5 stars3.50.00.00.00.61.71.3FHTXFoghorn Therapeutics2.4804 of 5 stars3.64.00.00.00.61.70.6GLUEMonte Rosa Therapeutics1.2465 of 5 stars3.30.00.00.00.61.70.6RNACCartesian Therapeutics1.3867 of 5 stars3.40.00.00.00.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 3.00Buy$17.80528.98% UpsideFHTXFoghorn Therapeutics 3.13Buy$12.13142.99% UpsideGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33220.11% UpsideRNACCartesian Therapeutics 2.83Moderate Buy$40.00224.41% UpsideCurrent Analyst Ratings BreakdownLatest ARTV, GLUE, RNAC, and FHTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025RNACCartesian TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.006/11/2025ARTVArtiva BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$12.005/15/2025ARTVArtiva BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.005/15/2025FHTXFoghorn TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$9.00 ➝ $9.005/14/2025FHTXFoghorn TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025RNACCartesian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K275.76N/AN/A$7.68 per share0.37FHTXFoghorn Therapeutics$22.60M12.31N/AN/A($0.82) per share-6.09GLUEMonte Rosa Therapeutics$75.62M3.90N/AN/A$3.63 per share1.32RNACCartesian Therapeutics$38.91M8.22N/AN/A($0.27) per share-45.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%8/7/2025 (Estimated)FHTXFoghorn Therapeutics-$86.62M-$1.36N/AN/AN/A-342.23%N/A-27.28%8/6/2025 (Estimated)GLUEMonte Rosa Therapeutics-$72.70M$0.0859.88N/AN/A3.86%2.65%1.65%8/14/2025 (Estimated)RNACCartesian Therapeutics-$77.42M-$52.83N/AN/AN/AN/AN/A-7.01%8/6/2025 (Estimated)Latest ARTV, GLUE, RNAC, and FHTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FHTXFoghorn Therapeutics-$0.32N/AN/AN/AN/AN/A8/14/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31N/AN/AN/A$7.23 millionN/A8/14/2025N/ARNACCartesian Therapeutics-$0.77N/AN/AN/A$0.77 millionN/A8/7/2025Q2 2025ARTVArtiva Biotherapeutics-$0.77N/AN/AN/AN/AN/A5/14/2025Q1 2025FHTXFoghorn Therapeutics-$0.30-$0.30N/A-$0.30$4.96 million$5.95 million5/8/2025Q1 2025ARTVArtiva Biotherapeutics-$0.68-$0.83-$0.15-$0.83N/AN/A5/8/2025Q1 2025GLUEMonte Rosa Therapeutics-$0.24$0.57+$0.81$0.57$13.57 million$84.93 million5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A13.9313.93FHTXFoghorn TherapeuticsN/A3.163.16GLUEMonte Rosa TherapeuticsN/A5.615.61RNACCartesian TherapeuticsN/A12.3412.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/AFHTXFoghorn Therapeutics61.55%GLUEMonte Rosa Therapeutics79.96%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%FHTXFoghorn Therapeutics7.58%GLUEMonte Rosa Therapeutics6.90%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.36 million19.15 millionN/AFHTXFoghorn Therapeutics12055.74 million51.52 millionOptionableGLUEMonte Rosa Therapeutics9061.51 million57.27 millionOptionableRNACCartesian Therapeutics6425.95 million10.30 millionOptionableARTV, GLUE, RNAC, and FHTX HeadlinesRecent News About These CompaniesCartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?July 24, 2025 | zacks.comBrokers Set Expectations for RNAC Q2 EarningsJuly 11, 2025 | marketbeat.comWedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform RecommendationJuly 9, 2025 | msn.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 9, 2025 | marketbeat.comCartesian Therapeutics (NASDAQ:RNAC) Earns Outperform Rating from Analysts at WedbushJuly 9, 2025 | marketbeat.comWe're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateJune 21, 2025 | finance.yahoo.comCartesian Therapeutics holds annual stockholders meetingJune 17, 2025 | investing.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisMay 30, 2025 | globenewswire.comCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 13, 2025 | manilatimes.netMAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comCartesian Therapeutics (RNAC) Gets a Buy from Mizuho SecuritiesMay 11, 2025 | theglobeandmail.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 11, 2025 | finance.yahoo.comCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWhy Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside PotentialMay 5, 2025 | insidermonkey.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2, 2025 | globenewswire.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%April 22, 2025 | aaii.comAWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 6.62%April 15, 2025 | aaii.comAWhy Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Up 21.84%April 15, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTV, GLUE, RNAC, and FHTX Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$2.83 -0.17 (-5.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.82 -0.02 (-0.53%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Foghorn Therapeutics NASDAQ:FHTX$4.99 -0.26 (-4.95%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.96 -0.03 (-0.50%) As of 08/1/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Monte Rosa Therapeutics NASDAQ:GLUE$4.79 -0.16 (-3.23%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.79 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$12.33 -0.48 (-3.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.32 -0.01 (-0.04%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
